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STUDY QUESTION:What is the prevalence of malignant testicular germ cell tumors (TGCT) and its precursors, (pre-) germ cell neoplasia
in situ (GCNIS), in late teenagers and adults who have androgen insensitivity syndrome (AIS) and the impact of an individual’s genetic suscepti-
bility to development of TGCT?
SUMMARY ANSWER: No GCNIS or TGCT was diagnosed, but pre-GCNIS was identiﬁed in 14 and 10% of complete and partial AIS
patients, respectively, and was associated with a higher genetic susceptibility score (GSS), with special attention for KITLG (rs995030) and
ATFZIP (rs2900333).
WHAT IS KNOWN ALREADY: Many adult women with AIS decline prophylactic gonadectomy, while data regarding the incidence,
pathophysiology and outcomes of TGCT in postpubertal individuals with AIS are lacking. The relevance of genetic factors, such as single
nucleotide polymorphisms (SNPs), in predisposing AIS individuals to TGCT is unknown.
STUDY DESIGN, SIZE, DURATION: This multicenter collaborative study on prophylactically removed gonadal tissue was conducted in
a pathology lab specialized in germ cell tumor biology.
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PARTICIPANTS/MATERIALS, SETTING, METHODS: Material from 52 postpubertal individuals with molecularly conﬁrmed AIS
(97 gonadal samples) was included; the median age at surgery was 17.5 (14–54) years. Immunohistochemical studies and high-throughput
proﬁling of 14 TGCT-associated SNPs were performed. The main outcome measures were the prevalence of pre-GCNIS, GCNIS and
TGCT, and its correlation with a GSS, developed based on the results of recent genome-wide association studies.
MAIN RESULTS AND ROLE OF CHANCE: The earliest recognizable change preceding GCNIS, referred to as pre-GCNIS, was present
in 14% of individuals with complete and 10% of those with partial AIS at a median age of 16 years. No GCNIS or invasive TGCT were found.
The median GSS was signiﬁcantly greater for those with, compared to those without, pre-GCNIS (P = 0.01), with an overlap between groups.
Our data suggest important roles for risk alleles G at KITLG (rs995030) and C at ATFZIP (rs2900333), among the 14 studied TGCT-
associated SNPs.
LARGE SCALE DATA: N/A.
LIMITATIONS REASONS FOR CAUTION: A limited number of cases were included.
WIDER IMPLICATIONS OF THE FINDINGS: Our data suggest that the prevalence of pre-GCNIS in individuals with AIS beyond
puberty is around 15%. Genetic susceptibility likely contributes to pre-GCNIS development in AIS but factors related to malignant progres-
sion remain unclear. Although data in older patients remain scarce, malignant progression appears to be a rare event, although the natural his-
tory of the premalignant lesion remains unknown. Therefore, the practice of routine prophylactic gonadectomy in adults with AIS appears
questionable and the patient’s preference, after having been fully informed, should be decisive in this matter.
STUDY FUNDING/COMPETING INTEREST(S): This study was supported by research grants from the Research Foundation
Flanders (FWO) (to M.C.), the Conselho Nacional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq G0D6713N) (to B.B.M. and M.C.)
and the European Society for Pediatric Endocrinology (ESPE), granted by Novo Nordisk AB (to J.K.). There are no competing interests.
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Introduction
Until the 21st century, bilateral gonadectomy was typically performed
in childhood following a diagnosis of 46,XY complete or partial andro-
gen insensitivity syndrome (CAIS, PAIS) in individuals raised in the
female sex, given that the historically reported increased risk of malig-
nant testicular germ cell tumors (TGCT) (Cools et al., 2006).
Reassuring data regarding TGCT risk in AIS during childhood have
since led to a testis sparing approach (Hughes et al., 2012), as many
affected individuals prefer to retain their gonads to take advantage of
the beneﬁts of endogenous hormone secretion. In individuals with
CAIS, postponing gonadectomy until late adolescence allows for
breast development, bone mass accrual and a pubertal growth spurt
through peripheral aromatization of androgens to oestrogens. Around
15% of adult women with CAIS subsequently refuse gonadectomy
(Deans et al., 2012). These women pose a challenge to caregivers
given the absence of reliable tumor biomarkers and the lack of data
regarding TGCT development in CAIS during adulthood (Cools et al.,
2014). Individuals with PAIS are now increasingly assigned to male sex
for rearing (Kolesinska et al., 2014) and their testes are retained.
However, apart from early orchidopexy of non-scrotal gonads, regular
self-examination, ultrasound and possibly testicular biopsy, no speciﬁc
recommendations for long-term monitoring have been made (Hughes
et al., 2012; van der Zwan et al., 2015).
The risk for development of TGCT speciﬁcally in adults with AIS has
never been investigated. Available estimates are derived from combin-
ing historical case series of patients who have undergone gonadectomy
after puberty. In a French study of 16 postpubertal girls (age range
11–18, mean 14 years) with molecularly conﬁrmed CAIS, the precursor
lesion carcinoma in situ (CIS), now ofﬁcially termed germ cell neoplasia
in situ (GCNIS) by the World Health Organization (Ulbright et al.,
2016), was diagnosed in one girl (6.3%) (Cheikhelard et al., 2008). No
malignancies were reported in 21 postpubertal woman (age range
14–40, mean 21 years) with molecularly conﬁrmed CAIS in a Spanish
study, however, testicular histology could be revised in only 13 of them
(Audi et al., 2010). In a British study, 25 adult women (age range
17–39, mean 23 years) with molecularly conﬁrmed CAIS underwent
magnetic resonance imaging of their gonads, followed by gonadectomy
in 13. No invasive tumors were detected in any of them, however three
had premalignant changes (Nakhal et al., 2013). These series predict a
combined GCNIS prevalence of 4/42 (9.5%) postpubertal girls and
adult women with CAIS between the ages of 11 and 40 years.
The histological changes in the testis in individuals with CAIS (age
range 3 months to 18 years), of which 9 were (post)pubertal, were
recently described (Kaprova-Pleskacova et al., 2014). The seminifer-
ous tubules are generally atrophic (ﬁbrosed and Sertoli cell-only) with
very few germ cells (GCs), depending on age and residual androgen
receptor (AR) activity. Twelve gonads of six women with CAIS older
than 13 years had no GCs. Two postpubertal women had pre-GCNIS,
and one had GCNIS, as deﬁned in the most recent WHO classiﬁcation
(Ulbright et al., 2016). These data and personal observations suggest
that the prevalence of invasive TGCT is substantially lower than the
prevalence of GCNIS, implying that progression of GCNIS to a TGCT
is a (very) rare event (Kaprova-Pleskacova et al., 2014).
Invasive TGCT in AIS can be seminoma, non-seminoma or a mixture
of both (Cools et al., 2005; Stoop et al., 2008). No reliable TGCT bio-
markers are currently available for the surveillance of testes at risk for
progression to an invasive tumor (Cools et al., 2014). In contrast to non-
seminomas, GCNIS and seminoma, being the most frequent neoplasia in
AIS, do not typically secrete proteins (e.g. β-hCG, α-fetoprotein)
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(Schmoll et al., 2004). Moreover, GCNIS cannot be visualized by ultra-
sound or MRI (Nakhal et al., 2013). TGCT, including GCNIS, express
speciﬁc microRNAs, that have potential roles as biomarkers when
secreted into body ﬂuids such as serum and semen (Dieckmann et al.,
2012). A recently developed diagnostic test based on the targeted detec-
tion of TGCT-speciﬁc microRNAs shows promising results for the diag-
nosis of early TGCT (Gillis et al., 2013) but not GCNIS (Van Agthoven
and Looijenga, 2016).
Genome-wide association studies (GWAS) have identiﬁed a number
of single nucleotide polymorphisms (SNPs) related to TGCT develop-
ment in the male population. A risk stratiﬁcation model has been pro-
posed based on the combined presence of one or more of these risk
alleles in an individual’s genotype (Kratz et al., 2011; Chung et al., 2013).
Independently, a polymorphic response element for the tumor suppres-
sor p53 within the promotor region of the KITLG gene (encoding KIT lig-
and) has been identiﬁed as an important genetic variant possibly
underlying TGCT susceptibility (Zeron-Medina et al., 2013). Whether
genetic susceptibility is a factor involved in TGCT development in AIS or
other differences of sex development has never been examined.
For the above reasons, there has been a strong demand for studies
assessing TGCT risk in postpubertal individuals with AIS speciﬁcally
and to help inform individualized management guidelines. We per-
formed detailed immunohistochemical studies in a relatively large ser-
ies of biopsy and gonadectomy samples from postpubertal individuals
with AIS aged 14 years or older. To avoid bias caused by inclusion of
patients with other conditions, only cases with a genetically conﬁrmed
diagnosis of AIS were included. Concomitantly, we performed geno-
typing of fourteen known TGCT susceptibility alleles and correlated
these data to the histopathological ﬁndings. These SNPs are all signiﬁ-
cantly related to TGCC (OR 1.19 or higher in at least two GWAS
studies), and map within or close to biologically relevant candidate
genes for disease-, gonadal- or GC development (Kanetsky et al.,
2011; Kratz et al., 2011; Chung et al., 2013; Zeron-Medina et al., 2013;
Litchﬁeld et al., 2017).
Materials andmethods
Ethics
The study was approved by the ethics review committees of the Ghent
University Hospital (MEC 2008/098) and Erasmus Medical Centre
Rotterdam (MEC 02.981). Samples were used according to the ‘Code for
Proper Secondary Use of Human Tissue in the Netherlands’, developed by
the Dutch Federation of Medical Scientiﬁc Societies, version 2011,
https://www.federa.org.
Tissue
Through international collaboration, we collected 97 gonadal tissue sam-
ples from 52 patients with a genetically conﬁrmed AR mutation (42 CAIS,
10 PAIS) (Table I). Samples were ﬁxed in formalin and sent as parafﬁn
blocks or 3–5 μm slides on coated glasses. All surgical procedures had
been performed with informed consent of the patients and/or their legal
guardians.
Immunohistochemistry
Slides were pre-treated with 3% H2O2 for 5 min, biotin blocked (Vector
SP-2001) and incubated overnight at 4°C with: Octamer-binding protein
3/4 (OCT3/4) (sc-5279, Santa Cruz Bio-technology, Santa Cruz, CA,
USA), 1/250 dilution; Testis Speciﬁc Protein on Y (TSPY) (provided by
Professor C. Lau, San Francisco, CA, USA), 1/3000 dilution; or KITLG (sc-
1302, Santa Cruz Bio-technology, Santa Cruz, CA, USA), 1/150 dilution.
Detection was done by 30 min incubation at room temperature with a
biotin-labeled secondary antibody followed by another 30 min incubation
with Avidin-Biotin-complex HRP conjugated. Visualization was performed
with DAB/H2O2 (OCT3/4) or New Fuchsin/Naphtali ASMX phosphate
(TSPY, KITLG) and counterstaining was with hematoxylin. For double-
staining experiments, visualization was done with different substrates: Fast
Blue/Naphtol ASMX phosphate (F3378 and N500, Sigma, Steinheim,
Germany) (blue) and 3-amino-9-ethyl-carbazole (A.5754 and D4254,
Sigma, Steinheim, Germany)/H2O2 (red), without counterstaining.
Morphological/immunohistochemical criteria
for GCNIS and preceding lesions
The criteria were according to Ulbright et al. (2016). Delayed maturation
of gonocytes is indicated by expression of octamer-binding protein 3/4
(OCT3/4) in centrally located gonocytes beyond the age of 6 months.
Pre-GCNIS is indicated by gonocytes, relocated from the center of the
tubules to the (pre-)spermatogonial niche at the basement membrane,
which fail to switch off OCT3/4 expression and may co-express OCT3/4
and TSPY in a heterogeneous pattern, accompanied by focal expression of
stem cell factor, alternatively called KIT Ligand (KITLG). The nuclei of pre-
GCNIS cells lack the characteristic features of the nuclei of GCNIS cells.
GCNIS is indicated by atypical gonocytes with enlarged, hyperchromatic
and angulated nuclei located at the basement membrane, with consistent
expression of OCT3/4 usually with co-expression of TSPY, and accom-
panied by diffuse KITLG expression in Sertoli cells and, in an autocrine
fashion, in GCNIS cells.
Conﬁrmation of ARmutation
Sanger sequencing of the full coding sequence of the AR gene was per-
formed according to standardized local procedures using genomic DNA
extracted from peripheral leukocytes. All mutations are reported based on
the coding DNA reference sequence according to Human Genome
Variation Society (HGVS) nomenclature (Table I).
SNP analysis
Genomic DNA was extracted from whole blood (if available) or tissue
samples according to standardized procedures. Genotyping of all selected
loci was based on published methods (Chung et al., 2013; Zeron-Medina
et al., 2013) (Table II) using TaqMan® SNP Genotyping Assays (Life
Technologies/Thermo Fisher Scientiﬁc, Bleiswijk, The Netherlands).
Fluorescent signal for allelic discrimination was obtained after PCR ampliﬁ-
cation using an end-point reading on the 7500 Fast Real-Time System (Life
Technologies). Automatic allele calling was performed with allelic discrim-
ination plot software (SDS 2.3, Life Technologies). The SNPs selected for
this study are all identiﬁed as signiﬁcantly related to TGCC susceptibility
(OR 1.19 or higher), and all map within or close to biologically relevant
candidate genes for disease-, gonadal- or GC development (see Table I
and Supplementary Table 1 for additional information). Furthermore the
SNPs nearby all genes speciﬁed in this study, with the exception of PPM1E,
have been identiﬁed in at least two independent GWAS studies (Kanetsky
et al., 2011; Kratz et al., 2011; Chung et al., 2013; Zeron-Medina et al.,
2013; Litchﬁeld et al., 2017).
GSS determination
The genetic susceptibility score (GSS) for developing a TGCT was calcu-
lated for each patient as follows: for each risk allele, the genotype fre-
quency of the risk allele was multiplied by the corresponding per allele
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Table I Characteristics of patients with 46,XY complete or partial androgen insensitivity syndrome (CAIS or PAIS).
Table 1 Patients ARmutation Sample type Macroscopy, histological data and genetic risk
ID Sample
ID
Ethnicity Age Nucleotide change Location Domain Anatomical
testes position#
GC (Pre-)GCNIS GSS P53bs
Clinical phenotype CAIS
1 1 Mixed-race* 31 c.386_387delGA (7) Exon 1 NTD G Abdominal ≤5 foci No 20.42 AG
2 G Abdominal >5 foci No
2 3 Caucasian* 17 c.2117A > G (1) (x9, CAIS) Exon 4 LBD G Abdominal >5 foci No 24.20 GG
4 G Abdominal ≤5 foci No
3 5 Caucasian* 34 c.2117A > G (1) (x9, CAIS) Exon 4 LBD G Inguinal ≤5 foci No 23.22 AG
6 G Inguinal no No
4 7 Caucasian* 17 c.2566 C > T (1) (x16, CAIS) Exon 7 LBD G Abdominal no No 15.52 AA
5 8 Caucasian* 16 c.2566 C > T (1) (x16, CAIS) Exon 7 LBD G Abdominal ≤5 foci No 19.34 AG
9 G Abdominal no No
6 10 Caucasian* 14 c.2338 C > T (2) (x7, CAIS) Exon 6 LBD G Inguinal >5 foci No 25.58 GG
11 G Inguinal >5 foci No
7 12 African
American*
20 c.2305 C > G (7) (x1, CAIS) Exon 5 LBD G Labial ≤5 foci No 25.64 GG
13 G Labial no No
8 14 Caucasian* 18 c.1530 C > T (7) Exon 1 NTD G NA ≤5 foci No 19.30 AG
15 G Inguinal >5 foci No
9 16 Caucasian* 34 c.1769-2A > G (4) (x1, CAIS) Intron
(Exon 2–3)
G Inguinal >5 foci No 21.76 GG
17 G Inguinal >5 foci No
10 18 Caucasian* 16 c.2257 C > T (2) (x6, CAIS) Exon 5 LBD G Abdominal no No 18 GG
19 G Abdominal ≤5 foci No
11 20 Caucasian* 31 c.1530 C > T (7) Exon 1 NTD G Abdominal no No 24.19 GG
21 G Abdominal No No
12 22 Caucasian* 29 c.2695A > T (7) (x4, PAIS) Exon 8 LBD G Inguinal Diffuse No NA NA
23 G Inguinal >5 foci No
13 24 Caucasian* 14 c.2695A > T (7) (x4, PAIS) Exon 8 LBD G Labial Diffuse No 21.69 GG
25 G Labial Diffuse No
14 26 Caucasian* 20 c.2695A > T (7) (x4, PAIS) Exon 8 LBD G Inguinal >5 foci No 16.80 AG
27 G Inguinal ≤5 foci No
15 28 Caucasian 18 c.521_533del (7) Exon 1 NTD G NA No No 27.06 GG
29 G NA No No
16 30 Caucasian 18 c.2674 T > C (7) Exon 8 LBD G Inguinal >5 foci Yes 26.99 GG
31 G Inguinal ≤5 foci Yes
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17 32 Caucasian 16 c.1774 C > T (7) Exon 3 DBD G NA >5 foci No NA AG
33 G NA No No
18 34 Caucasian 15 c.1847 G > A (7) (x11, CAIS, MAIS) Exon 3 DBD G NA >5 foci No 23.85 GG
35 G NA >5 foci No
19 36 Caucasian 18 c.2224 T > A (7) Exon 5 LBD G Abdominal ≤5 foci No 30.73 GG
37 G Abdominal No No
20 38 Caucasian 14 stop codon exon 1 (7) Exon 1 NTD G Inguinal Diffuse Yes 25.21 GG
39 G Inguinal Diffuse Yes
21 40 Caucasian 15 c.2350 C > T (7) Exon 6 LBD G Abdominal ≤5 foci No NA NA
22 41 Caucasian 17 deletion AR gene (2) Exons 1–8 all G Inguinal No No 25.63 GG
42 G Inguinal ≤5 foci No
23 43 Caucasian 15 c.1885 + 1 G > T (3) Intron G Abdominal >5 foci No NA GG
(Exon 3–4)
44 G Abdominal No No
24 45 Caucasian 18 c.1847 G > A (7) (x11, CAIS, MAIS) Exon 3 DBD G Abdominal No No 25.40 GG
46 G Abdominal No No
25 47 Caucasian 16 c.1617-2A > G (7) Intron G Abdominal ≤5 foci No NA GG
(Exon 1–2)
48 G Abdominal ≤5 foci No
26 49 Caucasian 16 c.2197 G > A (7) (x4, CAIS) Exon 5 LBD G Abdominal >5 foci No 22.68 GG
50 G Abdominal >5 foci No
27 51 Caucasian 16 c.832_833dup (7) Exon 1 NTD G Abdominal No No 21.58 GG
52 G Abdominal No No
28 53 Caucasian 15 c.2546dup (2) (x3, CAIS) Exon 7 LBD G Abdominal ≤5 foci Yes 36.89 GG
54 G Abdominal No No
29 55 Caucasian 15 c.2546dup (2) (x3, CAIS) Exon 7 LBD G Abdominal >5 foci Yes 36.89 AA
56 G Abdominal >5 foci Yes
30 57 Caucasian 46 c.2296 G > A (1) (x12, CAIS, PAIS) Exon 5 LBD G NA No No NA AG
58 G NA No No
31 59 Caucasian 27 c.1886-1 G > T (4) (x1, CAIS) Exon 4 LBD G NA No No NA GG
60 G NA >5 foci No
32 61 Caucasian 15 c.2546dup (2) (x3, CAIS) Exon 7 LBD G Abdominal >5 foci No 21.69 AG
62 G Abdominal >5 foci No
33 63 Caucasian 22 c.796dup (7) Exon 1 NTD G Inguinal >5 foci No 21 897 AG
64 G Inguinal Diffuse No
34 65 Caucasian 18 c.2112 C > G (7) Exon 5 LBD G Abdominal >5 foci No 18.33 AA
66 G Abdominal >5 foci No
35 67 Caucasian 17 c.2279 C > T (1) Exon 5 LBD B Abdominal No No NA NA
68 B Abdominal ≤5 foci No
Continued
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Table I Continued
Table 1 Patients ARmutation Sample type Macroscopy, histological data and genetic risk
ID Sample
ID
Ethnicity Age Nucleotide change Location Domain Anatomical
testes position#
GC (Pre-)GCNIS GSS P53bs
36 69 Caucasian 21 NA G Abdominal >5 foci Yes NA AG
70 G Abdominal diffuse No
37 71 Caucasian 18 c.2722 C > T (1) (x1, CAIS) Exon 8 LBD B Abdominal No No NA GG
72 B Abdominal No No
38 73 Caucasian 18 c.1696 G > T (7) Exon 2 DBD B Abdominal No No 21.15 GG
74 B Abdominal No No
39 75 Caucasian 17 c.1721 C > A (5) (x1, CAIS) Exon 2 DBD B Abdominal No No NA GG
40 76 Caucasian 14 c.2668 G > A (1) (x8, CAIS, PAIS) Exon 8 LBD G Abdominal ≤5 foci No NA AG
77 G Abdominal ≤5 foci No
41 78 Caucasian 41 NA G Abdominal No No 24.32 AG
79 G Abdominal No No
42 80 Caucasian 22 c.2677 C > T (1) (x6, CAIS) Exon 8 LBD B Inguinal >5 foci Yes 23.27 GG
Clinical phenotype PAIS
43§ 81 Caucasian 25 c.2521 C > A (7) Exon 7 LBD G Scrotal Diffuse No 24.58 NA
44§ 82 Caucasian 22 c.2567 G > A (1) Exon 7 LBD B Scrotal Diffuse No NA NA
83 B Scrotal Diffuse No
45§ 84 Caucasian 30 c.2567 G > A (1) (x19, CAIS, PAIS, MAIS) Exon 7 LBD B Scrotal >5 foci No NA NA
85 B Scrotal >5 foci No
46§ 86 Caucasian 54 c.2522 G > A (1) (x15, CAIS, PAIS) Exon 7 LBD G Inguinal ≤5 foci No NA GG
47§ 87 Caucasian 20 c.2567 G > A (1) Exon 7 LBD B Scrotal Diffuse No NA NA
88 B Scrotal Diffuse No
48° 89 Caucasian 15 c.2305 C > A (7) (x1, PAIS) Exon 5 LBD G NA >5 foci No 25.23 GG
90 G NA >5 foci No
49° 91 Caucasian 14 c.2305 C > A (7) (x1, PAIS) Exon 5 LBD G Inguinal >5 foci No 23.88 GG
92 G Inguinal >5 foci No
50§ 93 Caucasian 15 c.1301 C > T (6) (x1, PAIS) Exon 1 NTD B Inguinal Diffuse No NA GG
51° 94 Caucasian 15 c.2567 G > A (1) (x19, CAIS, PAIS, MAIS) Exon 7 LBD G Inguinal >5 foci No NA NA
95 G Inguinal >5 foci Yes
52° 96 Caucasian 16 c.503del (7) Exon 1 NTD G NA No No NA AG
97 G NA No No
*Brazilian patients; #: anatomical position at the time of biopsy / gonadectomy; §: PAIS individual living in the male gender; °: PAIS individual living in the female gender; ID: identiﬁcation number; AR: androgen receptor; G: gonadectomy; B: biopsy; NA:
information not available; GC: germ cells; GCNIS: neoplasia in situ; GSS, genetic susceptibility score; P53bs: binding site for tumor suppressor P53; DBD: DNA-binding domain; LBD: ligand-binding domain; NTD: N-terminal domain.
(1) Absent/low ligand binding; (2) Truncated/absent protein; (3) Affects donor splice site; (4) Affects acceptor splice site; (5) Defective DNA binding; (6) Reduced transactivation; (7) Mutation not reported/no functional studies performed.
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odds ratio (OR). The genotype frequency of the risk allele can be either 0,
1 or 2, depending on the number of actual risk alleles in the patients’ geno-
type. The sum of these individual products equals the GSS of that patient
(Kratz et al., 2011; Chung, et al., 2013). Because of the absence of an OR
for the SNP rs4590952, this SNP was not included in the GSS analyses, but
was investigated separately.
Statistics
IBM SPSS Statistics 22 was used for statistical analyses. Data that were not
normally distributed are expressed as median (25th–75th percentile),
unless otherwise stated. The Mann–Whitney U-test was used for compari-
son of non-parametric continuous variables.
Results
Testicular tissue samples (n = 97) were obtained from 42 women with
CAIS and 10 individuals with PAIS (6 men and 4 women). Four indivi-
duals with PAIS from two unrelated families (one from Germany, one
from Morocco) had the same, frequently occurring (Gottlieb et al.,
2012) mutation (Table I, patients 44, 45, 47 and 51). For most
patients, the clinical phenotype (CAIS versus PAIS) corresponded with
the phenotype in other reported cases with the same mutation.
Median age at surgery was 17.5 (range 14–54) years. Clinical data and
results are summarized in Table I. Due to the retrospective nature of
our study some patient data could not be retrieved. All procedures
were performed for prophylactic reasons (gonadectomy, 44 patients;
biopsy, 8 patients), sometimes after visualization of a testicular nodule
on ultrasound or MRI. All but two individuals (Table I, patients 1 and
7) are of Caucasian origin, from various countries. A schematic over-
view of the study design as well as results is given in Fig. 1.
GC, independent of their state, were present in 51/80 CAIS (64%)
and 15/17 (88%) PAIS samples. Diffusely distributed GC throughout
the testicular tissue investigated were more often present in PAIS than
in CAIS (Fig. 2). As reported previously, hamartomas, Sertoli cell only
nodules, branching tubules, thickening of the basal membrane, inter-
tubular ﬁbrosis, tubular atrophy and Leydig cell hyperplasia were com-
mon (Cools et al., 2005; Hannema et al., 2006, Kaprova-Pleskacova
et al., 2014). Lumen formation and limited spermatogenesis were seen
in some PAIS, but not in CAIS, samples.
Invasive TGCT or GCNIS were not encountered in this series. In
contrast, pre-GCNIS was found in tissue samples from 7/52 (13%)
individuals, who had a median age of 15 (range 14–22) years at the
.............................................................................................................................................................................................
Table II Overview of genetic variants included in the ﬁnal study and associated with a predisposition for the development
of GC cancer in the general male population.
SNP ID Gene Gene description Cytoband bp (b37) Non-risk/risk
allele
per allele
OR
Position of SNP
rs4657482 UCK2 Uridine-cytidine kinase 2 1q24.1 165 873 392 G/A 1.31 intergenic (only gene in LD
block)
rs17021463 HPGDS Hematopoietic prostaglandin two
synthase
4q22.3 95 224 812 G/T 1.19 intron variant
rs4699052 CENPE Centromere protein E 4q24 104 137 790 T/C 1.27 intergenic (only gene in LD
block)
rs2736100 TERT Telomerase reverse transcriptase 5p15.33 1 286 516 G/T 1.35 intron variant
rs4624820 SPRY4 Sprouty RTK signaling antagonist 4 5q31.3 141 681 788 G/A 1.47 intergenic (only gene in LD
block)
rs12699477 MAD1L1 Mad1 mitotic arrest deﬁcient like 1 7p22.3 1 968 953 T/C 1.21 intron variant
rs755383 DMRT1 Doublesex and mab-3 related
transcription factor 1
9p24.3 863.635 C/T 1.49 intron variant
rs2900333 ATF7IP Activating transcription factor 7-
interacting protein
12p13.1 14 653 867 T/C 1.23 3′ UTR variant
rs995030 KITLG KIT ligand 12q21.32 88 890 671 A/G 2.69 3′ UTR variant
rs4590952 KITLG
(p53bs)
KIT ligand p53 response element 12q21.32 88 953 659 A/G Unknown intron variant
rs1508595 KITLG KIT ligand 12q21.32 88 986 016 T/C 2.56 intergenic (only gene in LD
block)
rs4888262 RFWD3 Ring ﬁnger andWD repeat domain 3 16q23.1 74 670 458 T/C 1.26 coding sequence
(synonymous variant)
rs9905704 TEX14 Testis expressed 14, intercellular
bridge forming factor
17q22 56 632 543 G/T 1.27 intergenic
rs7221274 PPM1E Protein phosphatase Mg2+/Mn2+
dependent 1E
17q22 57 008 128 G/A 1.2 intron variant
SNP, single nucleotide polymorphism; ID, identiﬁcation; OR, odds ratio; bs, binding site.
To avoid inconsistent results for calculation of the GSS, two SNPs were excluded from the series of originally selected targets, i.e. rs210138 (BAK1, per allele OR 1.53) and
rs7040024 (DMRT1, per allele OR 1.7) due to poor data quality in some patients. This is likely explained by the fact that DNA had to be extracted from parafﬁn blocks in these
patients, resulting in poor quality and the impact of the amplicon size of these SNPs. In addition, rs459052 was not included in the GSS score (see text) because of the lack of an OR.
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time of surgery. Two of them (patient 20 and 42) had, in the months
before, experienced some discomfort in the groin region where their
testes were located; the decision to perform the procedure had been
taken after an ultrasound exam, yielding a heterogeneous appearance
of the testes. AR mutations were in the ligand-binding domain in 5/7
cases, in line with the known frequency distribution of AR mutations
causing AIS (Gottlieb et al., 2012).
One of ten individuals with PAIS (10%) had unilateral pre-GCNIS in
an inguinal gonad removed at 15 years. Pre-GCNIS was found in nine
samples (9/80, 11.3%) from six (6/42, 14.2%) women with CAIS
whose testes were removed at ages 14–22 years. Two of these
women (patients 28 and 29) were ﬁrst cousins. Bilateral samples were
available in ﬁve out of six cases, in three of these, the lesions were
bilateral. Fig. 3 displays representative images.
DNA was available from 36/52 (69%) individuals, including six out
of seven cases with pre-GCNIS. Allelic discrimination failed for two
SNPs (rs210138, BAK1, per allele OR 1.53 and rs7040024, DMRT1,
per allele OR 1.7) in most cases where DNA had to be extracted
from the parafﬁn blocks, yielding inconsistent results for calculation of
the GSS. This is likely related to poor quality of the isolated DNA, in
addition to the amplicon size of the speciﬁc genotyping assays for these
SNPs. Therefore, results for these SNPs were excluded from further
analysis from the original set of SNPs. Based on the 14 remaining SNPs
included in this study (see Table I), all cases were investigated. The so-
called GSS was calculated based on 13 of these 14 SNPS given that for
rs4590952, no OR is currently known. The GSS represents a patient
speciﬁc score related to the total sum of the individual SNP-risk allele
frequency multiplied by the corresponding allele OR. The GSS differed
signiﬁcantly in cases with and without pre-GCNIS (median [25th–75th
percentile] respectively 26.2 [24.7–36.9] versus 23.2 [21.0–25.3]; P =
0.01) (Fig. 4A). Of speciﬁc note is the observation that within this ser-
ies for two SNPs (KITLG, rs995030 and ATF7IP, RS2900333), all six
tested pre-GCNIS cases were homozygous for the risk alleles (G and
C respectively). Both genes have been related to cancer development
previously (Stoop et al., 2008; Turnbull et al., 2010). For these two
SNPs, allele frequency distribution differed signiﬁcantly between cases
with and without pre-GCNIS (rs995030: P = 0.05, rs2900333: P =
0.04).
Because of the absence of an OR for the SNP rs4590952, this SNP
is investigated separately. Allele frequency for the risk allele G at the
p53 binding site on the KITLG promotor (rs4590952) did not differ
between individuals with or without pre-GCNIS: four of six pre-
GCNIS cases (66%) were homozygous as compared to 24/38 (63%)
cases without pre-GCNIS (Fig. 4B).
Discussion
TGCT risk in AIS is lower than in many other disorders of sex develop-
ment (DSDs) (Cools et al., 2006). A major drawback in previous stud-
ies is that estimates of TGCT risk in CAIS are based on gonads
Figure 1 Schematic overview of the design of the study, both related to patients included as well as to SNPs investigated. Note that two of the ori-
ginal series of targets were excluded due to technical reasons (see text), resulting in a ﬁnal list of 14 SNPs (see Table I). One of these SNPs lacks an
odds ratio (OR), and was therefore not included in the ﬁnal genetic susceptibility score (GSS). CAIS/PAIS: complete/partial androgen insensitivity syn-
drome: GCNIS: germ cell neoplasia in situ; TGCT: testicular germ cell tumor.
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removed prophylactically early in life (Cools et al., 2005, 2006).
Clinical practice has changed, with gonadectomy mostly being post-
poned until late adolescence (Hughes et al., 2012). However, teen-
agers and women with CAIS increasingly object to gonadectomy, even
when counseled about the limitations of available TGCT screening
modalities (Deans et al., 2012). Furthermore, children with PAIS are
increasingly raised male, and for them, avoiding gonadectomy is crucial
(Kolesinska et al., 2014). The lack of data regarding long-term TGCT
risk in both CAIS and PAIS raises management challenges for patients
and clinicians.
Three factors contribute to the relatively low TGCT risk in AIS (van
der Zwan et al., 2015). First, testes develop normally in AIS, in contrast
to 46,XY gonadal dysgenesis, where TGCT risk is much higher.
Second, many GCs undergo apoptosis early and therefore have no
capacity for neoplastic transformation (Cools et al., 2005), and third,
the lack of paracrine androgen signaling may play a crucial role.
Androgens promote GC proliferation, mediated via Sertoli cells
(Cools et al., 2011; O’Shaughnessy, 2014). Immature Sertoli cells of
typical testes lack AR and therefore this effect only appears around
puberty (Rey, 2014). AIS is characterized by deﬁcient androgen signal-
ing. However, Wolfﬁan duct development in CAIS has been attributed
to residual paracrine androgen activity (Hannema et al., 2004). We
hypothesize that in AIS, similarly, residual paracrine androgen signaling
may promote neoplastic GC proliferation from puberty onwards,
resulting in increased TGCT risk in adulthood. We addressed this
question by investigating the occurrence of the earliest described
lesions predisposing to TGCT, as well as more advanced stages, in a
large series of AIS gonads obtained at ages 14 years and older. To
understand why only some individuals with AIS develop TGCTs, we
correlated our results to an estimation of each individual’s genetic sus-
ceptibility to develop TGCT, based on a selection of assumed relevant
(see Supplementary Table 1) high-risk SNPs identiﬁed in studies of tes-
ticular GC cancer in men (Kratz et al., 2011; Chung et al., 2013;
Zeron-Medina et al., 2013).
No invasive TGCT or extensive GCNIS were encountered in our
series containing almost 100 samples from 52 postpubertal individuals
with CAIS and PAIS. Pre-GCNIS was present in 6/42 women with
CAIS (14.2%) and 11/80 samples (11.3%). One pre-GCNIS lesion
was found in 1/10 individuals with PAIS (1/17 samples, 5.9%). These
percentages are comparable to combined data from other series
(Cheikhelard et al., 2008; Audi et al., 2010; Nakhal et al., 2013).
Surprisingly, in the current series, pre-GCNIS was not found more
often in individuals who have PAIS as compared to CAIS, in contrast
to earlier ﬁndings from our group (Cools et al., 2005, 2006).
Moreover, in cases who had pre-GCNIS, the clinical phenotype mostly
corresponded with that of other reported cases. TGCT incidence in
typical men differs largely among populations, with Caucasian men
having the highest incidence (Juniarto et al., 2013; Ghazarian et al.,
2015). Given that only two individuals from our series are non-
Caucasian, our study is not informative regarding this issue.
Based on our genotyping assay, the GSS for developing TGCT was
signiﬁcantly higher in individuals with pre-GCNIS as compared to those
without such lesions, suggesting that genetic susceptibility is one of the
factors involved in TGCT in AIS. However, there was considerable
overlap between the groups. Therefore we conclude that although
indicative, this approach as a whole is currently insufﬁciently discrimin-
atory as a guidance tool for management, e.g. regarding prophylactic
gonadectomy. Likewise, homozygosity for the reported high-risk p53
response element variant on the KITLG promotor was unable to pre-
dict (pre)malignancy. Looking in more detail at the individuals SNPs,
homozygosity for the risk allele was present in all pre-GCNIS cases for
SNPs in two relevant genes, namely in KITLG (rs995030) and in ATF7IP
(rs2900333), and their allele frequency distribution differed signiﬁcantly
between individuals with and without pre-GCNIS. KITLG is important
for GC survival and is aberrantly expressed in TGCT (Stoop et al.,
2008). Activating transcription factor 7-interacting protein (ATF7IP)
increases telomerase activity via telomerase reverse transcriptase
(TERT), and is overexpressed in various cancers (Turnbull et al.,
2010). These ﬁndings suggest that homozygosity for these risk alleles
may play a crucial role in the development of (the precursor of) TGCT
in AIS. However, these data need further conﬁrmation.
Of note, the risk alleles examined here have been related to invasive
TGCT. We cannot exclude that only some of these, possibly in com-
bination with other, hitherto unknown SNPs, are more relevant for
the development of GCNIS. Moreover, currently known TGCT SNPs
account for only a small portion of the genetic heritability (Litchﬁeld
et al., 2015). In ﬁve of seven pre-GCNIS cases, the AR mutation was in
the ligand-binding domain. It is currently not known if the AR genotype
or other factors, such as the number of CAG repeats, which has been
shown to modulate androgen sensitivity and to correlate with testicu-
lar cancer risk in typical men, may inﬂuence TGCT susceptibility in AIS
(Grassetti et al., 2015).
Individuals who had pre-GCNIS were relatively young, indicating
that these changes are present at an early age. Thus, a screening
biopsy to exclude pre-GCNIS, if deemed necessary, may be
Figure 2 Number of GCs, as identiﬁed by their positive immunos-
taining for testis speciﬁc protein on Y (TSPY), in relation to age.
Isolated nests of GCs persist into adulthood in many patients. The
presence of diffusely distributed GCs in the testicular tissue investi-
gated is more prevalent in PAIS than CAIS.
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Figure 3 Relevant staining results. (A) Focal presence of GCs (stained in red), without (pre-)malignant changes in a 22-year-old woman with CAIS.
TSPY, 130×. (B–F) Pre-GCNIS in a 15-year-old patient with PAIS: (B) GCs can be recognized by their red staining. TSPY, 300x. (C) Focal presence of pre-
malignant primordial GC-like cells (large cells, irregular nucleus, pale cytoplasm) on the basal membrane (arrows). There is marked Leydig cell hyperplasia in
between the tubules (arrowheads). HE, 350x. (D) Primordial GC-like cells are pluripotent and stain positive for OCT3/4 (brown). Their position on the
basal membrane differentiates them from GCs delayed in their maturation, which are in a luminal position. OCT3/4, 350x. (E) KITLG positivity (red stain-
ing) in the same area. KITLG, 450x. (F) Pre-GCNIS area: expansion of OCT3/4 (stained in blue) positive cells and combined OCT3/4 (blue) and TSPY
(red) positivity (arrowheads). OCT3/4-TSPY double staining, 200x. (G–J) Maturation delay and pre-GCNIS in a 14-year-old individual with CAIS: (G)
Diffuse presence of numerous TSPY positive (stained in red) GCs. TSPY, 100x. (H) Primordial germ cell like cells on the basal membrane, suspect of pre-
GCNIS (arrows). HE, 480x. (I) OCT3/4 positive (brown staining) luminal GCs, indicating maturation delay of GCs (arrowheads) in combination with
OCT3/4 positive (brown staining) GCs on the basal membrane, suggesting pre-neoplastic change of the cells (arrows). OCT3/4, 350x. (J) KITLG positivity
in the same area. KITLG, 400x.
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informative after completion of puberty, with the limitation that such a
biopsy is not necessarily representative of the testis as a whole. It is
worth noting that no neoplasia was present in samples from much old-
er individuals, even up to 54 years of age, suggesting that individual fac-
tors other than age likely play important roles. In spite of a relatively
high frequency of pre-GCNIS (10% in PAIS, 14% in CAIS in our study),
reassuringly, no invasive TGCT or extensive GCNIS was found in our
series or in other published reports. Indeed, regardless of the many
women who decline gonadectomy and an estimated large number of
individuals with AIS who do not obtain medical care, especially in
resource-limited countries, reports of invasive TGCT in AIS adults are
extremely rare (Cheikhelard et al., 2008; Audi et al., 2010; Juniarto
et al., 2013; Nakhal et al., 2013). This ﬁnding suggests that only a small
minority of these pre-GCNIS lesions will become invasive, a hypoth-
esis in line with a previous study of our group (Kaprova-Pleskacova
et al., 2014), possibly related to insufﬁcient androgen signaling to pro-
mote GC proliferation as outlined above. It remains to be identiﬁed
what the determining factors are in this particular process, in which
particular risk alleles might be involved. Overall, our ﬁndings support
the rationale of an individualized management approach, based on
informed decision making, rather than prophylactic removal of testes
in all adults with CAIS. Apart from percentage risk for pre-GCNIS,
GCNIS or malignant TGCT, factors such as limited availability of data
in older individuals with retained gonads, absence of reliable tumor
markers and imaging technologies, or eventual health consequences
resulting from unphysiological hormone replacement therapy after
gonadectomy, should be discussed.
In conclusion, we have shown that the prevalence of the earliest
neoplastic lesion, pre-GCNIS, in individuals with CAIS and PAIS, ran-
ging in age from 14 to 54 years is 10–15%; current data suggest,
Figure 4 (A) Boxplot of the genetic susceptibility score for TGCT in cases without pre-GCNIS as compared to cases with pre-GCNIS. (B)
Distribution of genotypes at the p53 binding site of the KITLG promotor in cases without pre-GCNIS (black bars) as compared to cases with pre-
GCNIS (gray bars). (C–D) Distribution of genotypes at the known risk alleles rs995030 in KITLG (C) and rs2900333 in ATF7IP (D) in cases without
pre-GCNIS (black bars) as compared to cases with pre-GCNIS (grey bars).
2571Germ cell tumor prevalence in AIS post puberty
Downloaded from https://academic.oup.com/humrep/article-abstract/32/12/2561/4600118
by Ghent University user
on 08 March 2018
however, that only a very small minority of these lesions will ever pro-
gress to invasive TGCT, questioning the current practice of prophylac-
tic gonadectomy in AIS, even in adults. Individuals with pre-GCNIS
had a signiﬁcantly greater genetic susceptibility to development of
TGCT based on presence of risk alleles for genes associated with
TGCT. Although, a speciﬁc set of SNPs has been found to predict
development of invasive TGCT in the testes of typical men, a SNP-
based screening test for AIS, such as that applied here, is in its current
form, insufﬁciently discriminatory to be used as a clinical management
tool.
Supplementary data
Supplementary data are available at Human Reproduction online.
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